LACDR launches training programme for innovative drug development
The Leiden Academic Centre for Drug Research (LACDR) has received a €750,000 grant from ZonMw for QPharmNL. This is a continuing education programme that trains professionals in computational techniques in pharmacology for innovative drug development.
‘The training we are going to develop is unique because it meets the needs of industry while giving professionals the opportunity to further develop their skills,’ says project leader Coen van Hasselt. ‘The programme combines our long-standing expertise in pharmacological research and education with close collaboration with pharmaceutical companies, consulting firms, regulatory bodies, and clinical practice.’
‘We are proud that LACDR can contribute to the principle of lifelong learning in this way’
The QPharmNL programme consists of six thematic modules and additional technical training in statistics, AI, and programming. The first module is expected to go live in early 2027. The project has been made possible thanks to the efforts of a large team within the LACDR, with contributions from both subject matter experts and specialists in innovative educational development.
The programme strengthens the knowledge and skills of professionals in the Dutch pharmaceutical sector, thereby contributing to the Netherlands' international position in the development of innovative medicines. Van Hasselt: ‘We are proud that LACDR can contribute to the principle of lifelong learning in this way.’
PharmaNL Human Capital Growth
The project is part of the Human Capital Growth programme line within PharmaNL, an initiative by ZonMw. In the coming months, five additional projects will launch. These projects focus specifically on developing flexible post-MBO, post-HBO, and post-academic education aligned with current developments in the pharmaceutical sector.